Impax Payment Was Meant To Dodge Competition, FTC Says
Drugmaker Impax Laboratories Inc. accepted an illegal payment from Endo Pharmaceuticals Inc. in exchange for delaying the market entry of Impax's generic form of Endo's opioid pain medication Opana ER, the...To view the full article, register now.
Already a subscriber? Click here to view full article